Linked Life Data

14649217

Source:http://linkedlifedata.com/resource/pubmed/id/14649217

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2003-11-27
pubmed:abstractText
Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. Aventis has submitted an NDA and an MAA to the FDA and the EMEA, respectively.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1472-4472
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1240-4
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Insulin glulisine. Aventis Pharma.
pubmed:affiliation
Istituto di Chimica Farmaceutica e Tossicologica, University of Milan, Viale Abruzzi 42, 20131 Milan, Italy. daniela.barlocco@unimi.it
pubmed:publicationType
Journal Article, Review